Arcus Biosciences (RCUS) stock drops as the company halts a late-stage trial for a lung cancer drug developed with Gilead ...

The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in ...

Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another trial—leading Gilead to pull further away from their once wide-ranging | ...

HIV franchise still drives growth, oncology M&A faces skepticism, & valuation looks cheap at ~16x P/E. Click for this GILD ...

Gilead Sciences has agreed to buy German clinical-stage biotechnology company Tubulis for up to $5 billion in a deal that bolsters the biopharmaceutical company’s oncology pipeline.

Gilead has struck a deal to buy Germany-based Tubulis for $3.15 billion upfront and up to $1.85 billion in milestones, securing an antibody-drug conjugate (ADC) candidate that is racing toward pivotal ...

Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences. Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn ...

Gilead Sciences agrees to buy German biotech company Tubulis for $3.15 billion upfront and $1.85 billion in contingency payments.

Gilead’s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and multiple prospects already in clinical testing.